title: Progression-free survival versus overall survival in ovarian cancer: where are we now?
authors.affiliation: Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK. susana.banerjee@rmh.nhs.uk
authors.forename: Susana
authors.initials: S
authors.lastname: Banerjee
authors.forename: Stan
authors.initials: S
authors.lastname: Kaye
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology; D010793:Phthalazines / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D000068258:Bevacizumab; C531550:olaparib